Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
This article was originally published in The Pink Sheet Daily
The financing is a first where a Korean start-up was able to attract an international syndicate of this stature, OrbiMed Caduceus Asia Partners Managing Director Chang said
You may also be interested in...
SEOUL - South Korean vaccine maker Green Cross recently signed a deal with Novartis to buy the latter's adjuvanted A/H1N1 vaccine MF59 to expand Green Cross' A/H1N1 vaccine production volume
OSONG, South Korea - The worldwide market for biotech and other pharmaceutical companies seeking funds through initial public offers is closed for at least a year and other sources of money are becoming scarce as well, venture capital firms said during the annual Bio Korea conference in Osong, South Korea
SINGAPORE - The swing from big pharma to biotech has captured investor attention, and has changed the nature of the types of investments that venture capitalists are making. Many are willing to take bigger risks in Asia and are opting in earlier rather than as pipelines mature, making intellectual property protection even more critical, a panel of investors said during the BioMedical Asia 2008 conference in Singapore April 15